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OBJECTIVES: Anti-tumour necrosis factor inhibitor (anti-TNF) therapy has been
widely and successfully used in patients with rheumatoid arthritis (RA). However,
about 30% of these patients have an inadequate response to these medicines.
Abatacept has shown significant clinical and functional benefits in patients who
have inadequate response to anti-TNF therapy. The aim of this analysis is to ex-
amine the cost-effectiveness of abatacept after the failure of a first anti-TNF.
METHODS: A patient simulation model was constructed using clinical data from
the (abatacept) ATTAIN trial and the British Society for Rheumatology Biologics
Register (BSRBR). The time horizon of this model was lifetime. Clinical effective-
ness was evaluated by changes in Health Assessment Questionnaire (HAQ) score
from baseline up to 12 months. Patients discontinued treatment due to a lack of
efficacy or adverse events. After treatment discontinuation, patients received sup-
portive care, regardless of treatment group. Utilities were obtained by mapping
HAQ to EQ-5D. Cost inputs included drug and administration, monitoring, medical
costs associated with HAQ level, and joint replacement costs obtained from pub-
lished literature and inflated to 2009 British pounds. RESULTS: Abatacept was es-
timated to yield 1.06 additional quality-adjusted life years (QALYs) per patient (3.28
vs. 2.22) over a lifetime, compared to conventional DMARDs. The total lifetime
costs associated with abatacept were £46,522 and total costs for conventional
DMARDs were £17,025, resulting in an incremental cost-effectiveness ratio (ICER) of
£27,936 per QALY gained. Probabilistic and univariate sensitivity analyses con-
firmed the robustness of our findings. CONCLUSIONS:Abatacept is a cost-effective
treatment option for patients with RA after the failure of a first anti-TNF in the UK.
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OBJECTIVES: Rheumatoid Arthrtis (RA) leads to significant impact on management
costs and patient’s quality of life. In Venezuela, annual per capita cost for RA
management increased from 698USD in 1997 to 3494USD in 2002. Biologic treat-
ment after disease-modifying antirheumatic drugs fail is an alternative, but their
high cost represents a challenge for decision makers. This study aims to perform
cost-effectiveness and cost-utility analysis of biologic alternatives for moderate to
severe RA in Venezuela. METHODS: An economic analysis was developed through
a decision-tree model to simulate RA evolution after treatment with etanercept
(basecase treatment), adalimumab, infliximab, tocilizumab or rituximab as first-
line therapies and their associated costs over a 12-month time horizon. Therapy
continuation or switch was evaluated at week 24. Effectiveness measures were
ACR70 response and quality adjusted life years (QALYs) gained. Direct medical
costs included biologics, concomitant drugs, medical follow-up and adverse events
management. Clinical response was extracted from published literature, while
costs were collected from Venezuelan public official databases. Probabilistic sen-
sitivity analyses were performed through Monte Carlo Simulation second-order
approach. RESULTS: In base case analysis estimated effectiveness resulted in
[ACR70,QALY]: etanercept [31.3%,0.79]; adalimumab [18.1%,0.77]; infliximab
[12.8%,0.73]; tocilizumab [21.1%,0.77] and rituximab [11.9%, 0.75]. Expected mean
costs per patient were 13,588USD, 15,451USD; 15,950USD; 18,705USD and
14,350USD, respectively. In cost-effectiveness and cost-utility analysis, etanercept
was the least costly and the most effective alternative being cost-saving in all
comparisons: 5117USD less than tocilizumab (most costly alternative); 19.4% more
patients met ACR70 response regarding rituximab (the least effective alternatives);
incremental utility reached0.0576 QALYs versus infliximab. Acceptability curves
showed that etanercept regardless willingness to pay would be the most cost-
effective biologic. CONCLUSIONS: Due to its lower costs and favorable effective-
ness profile, etanercept is dominant regarding ACR70 response and QALYs gained
over other biologic treatments in the management of RA at Venezuelan public
health care system.
PMS33
ECONOMIC EVALUATION OF INTRAVENOUSLY IBANDRONATE FOR THE
TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN MEXICO
Carlos F1, Clark P2, Lechuga D3
1R A C Salud Consultores S.A. de C.V., Mexico City, Mexico, 2Hospital Infantil Federico Gómez,
Secretaría de Salud, Mexico, Mexico, Mexico, 3Roche Mexico, Mexico, Mexico, Mexico
OBJECTIVES: Osteoporosis (OP) and fragility fractures (FF) significantly affect both
mortality and health-related-quality-of-life, causing high costs. We aimed to de-
termine the cost and the effectiveness of three different bisphosphonates (BP) in
Mexico. METHODS: A six health-state life-time Markov microsimulation model
was adapted to compare intravenously (IV) ibandronate 3mg injection every 3
months (IBD), oral weekly (OW) alendronate 70mg (ALD) and OW risedronate 35mg
(RSD), under the perspective of the public health care system in Mexico. Target
population consists of postmenopausal (PW) women over 50 years with or without
prior fracture. Only direct costs were accounted for and these included drug acqui-
sition and acute medical attention of FF. All costs are expressed in 2009 United
States dollars (USD). Unit cost and antifracture efficacy was derived from published
literature. Outcomes measures were the type and frequency of FF avoided with
each agent compared with no treatment and quality-adjusted life years (QALY).
Cost and efficacy were calculated taking into account persistence and compliance
data. RESULTS: The avoided fractures rate was higher with IV IBD (644 per 10,000
patients Vs. 205 and 203 with ALD and RSD, respectively). When compared with
OW BP, IV IBD reduced the total FF frequency in about 10%. Hence, the use of IV IBD
resulted in a gain of 37 QALY per every 1,000 patients. The incremental cost per
QALY gained with IV IBD ranged from 9898 USD (vs. ALD) to 15,047 USD (vs. RSD).
The gross domestic product per capita in Mexico during 2009 was estimated at 8337
USD. Results were robust to variation in all parameters. CONCLUSIONS: By reduc-
ing significantly the number of doses needed per year, IV IBD improves adherence
and decrease the expected frequency of FF in comparison with OW BF. These
results suggest that IV IBD is a cost-effective intervention for PM OP in Mexico.
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BACKGROUND: Osteoarthritis (OA) is the most common rheumatic disease in the
world and one of the main causes of joint pain and disability of the adult popula-
tion; it therefore represents an important use of medical resources for the institu-
tions and compromises the quality of life of patients. OBJECTIVES: To analyze the
cost-effectiveness of Bio-HA vs. Hilano G-F20 in patients with knee osteoarthritis.
METHODS: We conducted an economic evaluation. The alternatives to compare
were Bio-HA vs Hilano, administered three weekly injections, with follow-up eval-
uations at week 12. The perspective is the Mexican Social Security Institute (IMSS).
The economic model included the cost of drug acquisition and management of
adverse events (AE). The use of resources associated with each AE was defined
according to a Delphi Panel. The efficacy measure was the proportion of patients
with OMERACT-OARSI response, obtained from a head to head analysis (Onel E,
2008).RESULTS:The response rates for Bio-HA were 71% versus 63% for Hilano. The
knee effusions in patients treated with Bio-HA was 0.6% (MX$39) vs. Hilano 8.1%
(MX$531). The cost per patient treated for each alternative was MX$7728 and
MX$8338 for Bio-HA and Hilano, respectively. The cost per responder patient was
lower for Bio-HA than Hilano, MX $10,885 and MX $13,236, respectively. So, the
savings generated by Bio-HA are very high. If we consider the 1,000 patients for
each alternative, the savings would be MX$610,000 and this money be useful to
purchase an extra 122 cycles of treatment with Bio-HA or to be reassign for other
therapeutic areas. Considering all the above Bio-HA proved to be a dominant strat-
egy (less costly and more effective). CONCLUSIONS: The results of this pharmaco-
economic analysis suggest that the use of Bio-HA in patients with OA is a cost-
saving strategy for the institutions of public health in Mexico.
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OBJECTIVES: To evaluate the cost-effectiveness of denosumab compared to sup-
portive care (no active osteoporosis treatment), alendronate, ibandronate, risend-
ronate and strontium ranelate for the treatment of women with post-menopausal
osteoporosis (PMO) in Greece.METHODS:An 8-state, 6-month cycle Markov cohort
model was developed in order to estimate costs and effects, i.e. reductions in
fracture occurrence, of denosumab vs. comparators for a 5year period, from a
third-party payer perspective (Euros, 2011). The model was populated according to
the characteristics of the FREEDOM clinical trial population (mean age: 72.3, prev-
alence of vertebral fracture: 23.6%, femoral neck T-score2.5), that also provided
the data on efficacy of denosumab. Data on efficacy (relative risk of fractures) for
the comparators were taken from a published meta-analysis. The model took into
account treatment persistence across all comparators, as well as a 2year residual
effect of treatment after discontinuation. RESULTS: The base-case analysis
showed that the incremental cost per QALY gained with denosumab was €18,813,
€24,784, €13,727, €18,436 and €11,114 versus no treatment, alendronate, ibandro-
nate, risendronate and strontium ranelate, respectively. The probabilistic sensitiv-
ity analysis demonstrated that denosumab was cost-effective in an implicit €30,000
threshold for 81.6% of the iterations versus no treatment and risendronate, 63.4%
versus no treatment and alendronate and 88.2% versus no treatment and ibandro-
nate. Univariate sensitivity analyses showed that changes in persistence rates,
baseline age and T-score where the factors with the most significant influence in
the results. CONCLUSIONS: In a disease that entails a significant morbidity and
socioeconomic burden, denosumab seems to be a cost-effective alternative to es-
tablished treatment regimens for osteoporosis in Greece.
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OBJECTIVES: Rheumatoid Arthrtis (RA) leads to significant impact on management
costs and patient’s quality of life if no therapeutic measure is adopted and repre-
sents one of five most common incapacity causes in women aged 15-44 years, in
Colombia. Biologic treatment after disease-modifying antirheumatic drugs fail is
an alternative, but their high cost represents a challenge for decision makers. This
study aims to perform cost-effectiveness and cost-utility analysis of biologic alter-
natives for moderate to severe RA in Colombia, from a public perspective.
METHODS: An economic analysis was developed through a decision-tree model to
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